
Sakar Healthcare (SAKAR) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
502.4M
Gross Profit
355.7M
70.80%
Operating Income
102.5M
20.40%
Net Income
57.6M
11.47%
Balance Sheet Metrics
Total Assets
4.2B
Total Liabilities
1.3B
Shareholders Equity
2.9B
Debt to Equity
0.45
Cash Flow Metrics
Revenue & Profitability Trend
Sakar Healthcare Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.8B | 1.5B | 1.3B | 1.3B | 947.4M |
Cost of Goods Sold | 822.6M | 836.8M | 737.9M | 748.1M | 514.9M |
Gross Profit | 953.2M | 696.7M | 595.7M | 534.1M | 432.5M |
Gross Margin % | 53.7% | 45.4% | 44.7% | 41.7% | 45.6% |
Operating Expenses | |||||
Research & Development | - | 6.2M | 7.5M | 1.1M | 121.0K |
Selling, General & Administrative | - | 21.6M | 12.1M | 9.0M | 9.5M |
Other Operating Expenses | 139.9M | 87.2M | 75.7M | 77.6M | 64.1M |
Total Operating Expenses | 139.9M | 115.0M | 95.3M | 87.8M | 73.7M |
Operating Income | 288.0M | 211.5M | 191.2M | 206.4M | 151.2M |
Operating Margin % | 16.2% | 13.8% | 14.3% | 16.1% | 16.0% |
Non-Operating Items | |||||
Interest Income | - | 1.3M | 2.7M | 0 | 163.0K |
Interest Expense | 85.4M | 67.5M | 54.9M | 25.9M | 1.7M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 215.3M | 159.0M | 168.8M | 190.1M | 132.3M |
Income Tax | 40.3M | 42.3M | 41.2M | 37.7M | 25.5M |
Effective Tax Rate % | 18.7% | 26.6% | 24.4% | 19.8% | 19.3% |
Net Income | 175.0M | 116.7M | 127.6M | 152.4M | 106.8M |
Net Margin % | 9.9% | 7.6% | 9.6% | 11.9% | 11.3% |
Key Metrics | |||||
EBITDA | 510.0M | 404.0M | 374.7M | 312.0M | 214.6M |
EPS (Basic) | - | ₹5.69 | ₹6.86 | ₹10.09 | ₹708.58 |
EPS (Diluted) | - | ₹5.69 | ₹6.86 | ₹10.09 | ₹708.58 |
Basic Shares Outstanding | - | 20525000 | 18593000 | 15100000 | 150760 |
Diluted Shares Outstanding | - | 20525000 | 18593000 | 15100000 | 150760 |
Income Statement Trend
Sakar Healthcare Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.0M | 2.6M | 933.0K | 298.0K | 825.0K |
Short-term Investments | 2.1M | 2.1M | 34.3M | 71.1M | - |
Accounts Receivable | 307.2M | 209.1M | 220.8M | 141.8M | 123.7M |
Inventory | 435.9M | 277.3M | 154.0M | 141.8M | 157.0M |
Other Current Assets | 141.0M | - | - | 2.0K | - |
Total Current Assets | 887.3M | 716.1M | 559.2M | 500.2M | 337.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.0B | 437.6M | 392.6M | 2.0B | 170.8M |
Goodwill | 46.1M | 14.6M | 0 | 0 | 7.3M |
Intangible Assets | 46.1M | 14.6M | - | - | 7.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 5.7M | 96.0K | 93.0K | 1.0K | 1.0K |
Total Non-Current Assets | 3.3B | 3.2B | 2.8B | 2.2B | 1.4B |
Total Assets | 4.2B | 3.9B | 3.4B | 2.7B | 1.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 210.7M | 274.5M | 260.9M | 305.0M | 197.8M |
Short-term Debt | 213.6M | 244.0M | 209.5M | 78.5M | 41.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 80.1M | 40.0M | 34.4M | 29.9M | 22.2M |
Total Current Liabilities | 631.9M | 590.6M | 544.9M | 467.8M | 332.7M |
Non-Current Liabilities | |||||
Long-term Debt | 535.9M | 549.6M | 982.3M | 850.1M | 384.5M |
Deferred Tax Liabilities | 103.4M | 100.2M | 85.7M | 70.9M | 68.3M |
Other Non-Current Liabilities | - | - | -1.0K | -1.0K | - |
Total Non-Current Liabilities | 666.0M | 672.7M | 1.1B | 935.4M | 460.7M |
Total Liabilities | 1.3B | 1.3B | 1.6B | 1.4B | 793.4M |
Equity | |||||
Common Stock | 219.5M | 217.5M | 190.4M | 171.2M | 156.2M |
Retained Earnings | - | 805.4M | 688.6M | 561.1M | 409.4M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.9B | 2.6B | 1.7B | 1.3B | 984.5M |
Key Metrics | |||||
Total Debt | 749.5M | 793.5M | 1.2B | 928.6M | 426.0M |
Working Capital | 255.4M | 125.5M | 14.2M | 32.5M | 4.5M |
Balance Sheet Composition
Sakar Healthcare Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 215.3M | 159.0M | 168.8M | 190.1M | 132.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -68.7M | -152.8M | 47.5M | -53.0M | -95.9M |
Operating Cash Flow | 223.7M | 73.1M | 271.0M | 145.4M | 44.8M |
Investing Activities | |||||
Capital Expenditures | -322.8M | -595.6M | -822.0M | -355.5M | -468.3M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | 0 | 0 | 0 | 0 |
Investment Sales | 0 | 31.4M | 38.0M | 0 | 0 |
Investing Cash Flow | -307.1M | -515.4M | -743.8M | -468.3M | -468.3M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | 0 | 982.3M | 937.1M | 381.2M |
Debt Repayment | -13.6M | 0 | 0 | -19.6M | -120.6M |
Financing Cash Flow | 44.0M | 774.2M | 1.3B | 976.7M | 319.8M |
Free Cash Flow | 17.5M | -350.9M | -488.5M | -109.1M | -322.6M |
Net Change in Cash | -39.4M | 331.9M | 843.1M | 653.8M | -103.8M |
Cash Flow Trend
Sakar Healthcare Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
40.28
Price to Book
2.43
Price to Sales
3.69
Profitability Ratios
Profit Margin
10.45%
Operating Margin
13.53%
Return on Equity
6.13%
Return on Assets
4.21%
Financial Health
Current Ratio
1.40
Debt to Equity
30.26
Beta
0.06
Per Share Data
EPS (TTM)
₹7.96
Book Value per Share
₹131.81
Revenue per Share
₹85.94
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
sakar | 7.0B | 40.28 | 2.43 | 6.13% | 10.45% | 30.26 |
Sun Pharmaceutical | 3.9T | 37.74 | 5.43 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.87 | 10.91 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 47.8B | -13.92 | -21.95 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 43.0B | 22.81 | 3.14 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 44.3B | 153.95 | 6.28 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.